Obexelimab almost completely prevented new inflammatory lesions visible on brain scans of adults with relapsing MS, per trial data.

Radiomics offers improved assessment of spinal cord pathology in MS, surpassing conventional MRI in precision and sensitivity ...

The Justice Department unexpectedly dropped charges against a neuroscientist indicted for defrauding the NIH of approximately ...

A pivotal clinical development has sent Zenas BioPharma (NASDAQ: ZBIO) shares climbing higher, reshaping the company’s ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas ...

The new guidance for neurologists comes in updates to the McDonald criteria, the checklist doctors use to diagnose multiple sclerosis.

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a study titled A Randomized ...

Their legs starred in an advert highlighting multiple sclerosis, a condition striking more young women than ever. Now read their fascinating stories ...

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

Heavy drinkers who have eight or more alcoholic drinks per week have an increased risk of brain lesions called hyaline arteriolosclerosis, signs of brain injury that are associated with memory and ...

Metis' MTS-004 was safe and eased symptoms of pseudobulbar affect in people with MS and other neurological disorders, trial data show.

Olfactory dysfunction in MS may be linked to nasal microbial changes, not just central inflammation. MS patients showed lower ...